The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Official Title: A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)
Study ID: NCT05153330
Brief Summary: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL.
Detailed Description: A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) with mixed lineage leukemia 1-rearranged (KMT2A/ MLL1r), nucleophosmin 1 (NPM1), diffuse large b-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic lymphoma (CLL)/ small lymphocytic lymphoma (SLL).
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California, Irvine, Irvine, California, United States
University of Southern California Norris Cancer Center, Los Angeles, California, United States
UCLA Department of Medicine, Los Angeles, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Stanford Cancer Center, Stanford, California, United States
Mayo Clinic, Jacksonville, Florida, United States
Mount Sinai Medical Center, Miami Beach, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Blood & Marrow Transplant Group of GA (Northside Hospital), Atlanta, Georgia, United States
Northwestern University, Chicago, Illinois, United States
Henry Ford Hospital, Detroit, Michigan, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Vanderbilt University Medical Center, Nashville, Tennessee, United States
MD Anderson Cancer Center, Houston, Texas, United States
Virginia Cancer Specialists, Gainesville, Virginia, United States
Evangelismos General Hospital of Athens, Athens, , Greece
Alexandra General Hospital of Athens, Athens, , Greece
AOU Ospedali Riuniti Ancona, Ancona, , Italy
ASST Papa Giovanni XXIII Hospital Bergamo, Bergamo, , Italy
Istituto Europeo di Oncologia, Milano, , Italy
Instituto Clinico Humanitas, Milan, , Italy
IRCCS Ospedale San Raffaele, Programma di Ricerca Strategica su LLC, Milan, , Italy
Ospedale Santa Maria della Misericordia, Perugia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, , Italy
Amsterdam UMC, Amsterdam, , Netherlands
UMCG Groningen, Groningen, , Netherlands
Radboud University Medical Center, Nijmegen, , Netherlands
Erasmus University Medical Center Rotterdam, Rotterdam, , Netherlands
Hospital General de Albacete, Albacete, , Spain
Hospital Clinic de Barcelona, Barcelona, , Spain
Institut Catala d'Oncologia, Barcelona, , Spain
Hospital San Pedro de Alcántara, Cáceres, , Spain
Hospital Universitario de la Princesa, Madrid, , Spain
Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Hospital Universitario 12 de Octubre, Madrid, , Spain
Hospital Universitario Central de Asturias, Oviedo, , Spain
Hospital Universitario de Salamanca, Salamanca, , Spain
Hospital Universitario Virgen del Rocio, Sevilla, , Spain
Hospital Universitario y Politécnico La Fe, Valencia, , Spain
Name: Alex Cacovean, MD
Affiliation: Biomea Fusion Inc.
Role: STUDY_DIRECTOR